I admit it's sometimes difficult to look too far down the road when
the market continues to head higher regardless of the economic news. My
investments have fared well as of late, and anyone who's been an
optimist over the past four years is probably doing well, too. But the
market doesn't have much regard for the past; it's all about what's in
the future that often drives stocks. That's why I want to look at a
sector that's poised for big gains over the next decade: the health care
sector.
I understand there's plenty of animosity toward the sector because of
high branded-drug prices and a long, drawn-out, drug development
process, but there are five reasons why health care represents your best
investment choice over the coming decade rather than traditionally
strong sectors like technology or financials.
1. Lab-based sequencing costs are falling dramatically
There
is one primary reason why research costs are contributing to better
drugs coming down our pipeline: Big technological advancements over the
past decade.
Drug research all begins in the lab. According to the U.S. National
Institutes of Health, there are more than 140,000 clinical studies
currently under way. This figure has ballooned since 2000 as higher
quality genome-sequencing equipment and better in-lab instrumentation
has allowed researchers to conduct significantly more studies for the
same previous cost.
The chart above means a big boost in human genome sequencing demand for Life Technologies (NASDAQ: LIFE )
. Life Tech introduced its Benchtop Ion Proton Sequencer in January
last year for a price of just $149,000 and touted its ability to sequence the human genome in a single day
for just $1,000. Previous versions had cost anywhere from
$500,000-$750,000 and took weeks or months to sequence the human genome
at a cost of $5,000 to $10,000 a pop. (more)
Please bookmark us
No comments:
Post a Comment